By knocking out a protein duo’s “bodyguard” role, researchers have exposed a hidden weakness in pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. Both are abnormally abundant in pancreatic tumors compared with normal tissue and they work hand-in-hand to create resistance to treatment in pancreatic cancer cells. The researchers used CRISPR/Cas9 gene editing and small interfering RNA (siRNA) to reduce or “knock down” the expression of PRDX1 from pancreatic cancer cells. And, because other cancers rely on oxidative/redox signaling, this dual-targeting approach could extend beyond pancreatic cancer to other forms of aggressive cancer.